Process for antibody directed enzyme prodrug therapy

Details Process for antibody directed enzyme prodrug therapy Process for antibody directed enzyme prodrug therapy

1995-05-16

1997-08-26

Achutamurthy, Ponnathapura

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

4241821, 514476, 560134, 560135, 560136, 560137, A61K 39395, C07K 1600, C07C26100, C07F 902

Patent

active

056608292

ABSTRACT:
Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.

REFERENCES:
patent: 4975278 (1990-12-01), Senter et al.
patent: 5405990 (1995-04-01), Burke et al.
Bagshawe, K.D., Tumour Site Activation of Cytotoxic Agent; Advances in Applications of Monoclonal Antibodies in Clinical Oncology; Hammersmith Hospital Meeting; 1988.
Bagshawe, K.D., Antibody Directed Enzymes Acivate Anti-Cancer Prodrugs Biochem Soc Trans; 1990.
Parasmickiene, Izn. Akad. Nauk. SSSR Ser. Khim. (3) 649-51 (1971).
Karpavicius, Izv. Akad. Nauk. SSSR Ser. Khim (3) 2150-3 (1970).
CAS/STN-Search Report.
G. Parasmickiene et al., `Synthesis of amino acid derivatives acylated by p-[bis(2-chloropropyl)amino]phenyl alkanoic acids` Chemical Abstracts, vol. 75, No. 5; Aug. 2, 1971, p. 564, Abstract No. 36603m.
K. Karpavicius et al., `N-p-[Bis(2-chloroethyl)amino]phenylacetyl dicarboxylic amino acids and their derivatives` Chemical Abstracts, vol. 75, No. 1; Jul. 5, 1971, p. 526, Abstract No. 6299z.
M. H. Benn et al., `Cytotoxic Compounds. Part II. Some Amides of the "Nitrogen Mustard" type.` Journal of the Chemical Society 1961; pp. 2365-2375.
P.D. Edwards et al., `Cytotoxic compounds Part XVII. o-,m-, and p-Bis(2-chloroethylamino)phenol,p-[N-(2-chloroethyl methylamino]phenol, N,N-[bis-2-chloroethyl-p-phenylenediamine], and N,N-bis(2-chloroethyl)-N'-methyl-p-phe nylenediamine as sources of biologically active carbamates`; Journal of the Chemical Society, Perkin Transactions a, No. 20, 1973 pp. 2397, -2402.
Edwards/Foster/Owen/Pringle: Cytotoxic Compounds XVII; Perkin J.C.S., 1 (1973): 2397-2402.
Benn/Creighton/Owen/White: Cytotoxic Compounds II (1961): 2365-2375.
Wilman, D. E. V.: Prodrugs in Cancer Chemotheraphy: Biochem. Soc. Trans. 14 (1986): 375-382.
Springer, C.J., J. Med. Chem., 33, (1990), 677-681.
Levy C.C., J. Bio. Chem., 212, (1967), 2933-2938.
Pratt, A. G., J. Med. Chem., 243, (1968), 6367-6372.
Levy, C.C., J. Bio Chem., 242, (1967), 2933-2938.
McCullough, J.L., J. Bio Chem., 246, (1971), 7207-7213.
Goldman, P., Proc. N.A.S., 58, (1967), 1299-1306.
Rosowsky, A., Progress in Medicinal Chemistry, 26, (1990), 145-159.
Adamson P.C., J. Clinical Oncology, 10, (1992), 1359-1364.
Bisset, G.M.F., J. Med. Chem., 35, (1992), 859-866.
Sherwood, R.F., Eur. J. Biochem., 148 (1985), 447-453.
Bagshawe K.D., Br. J. Cancer, 58, (1988) 700-703.
Springer C.J., J. Med. Chem., 33 (1990), 677-681.
Antoniw C.J., Br. J. Cancer, 62, (1990), 909-914.
Mann, J., Tetrahedron, 46, (1990), 5377-5382.
Springer, C.J., Eur J. Cancer, 27, (1991), 1361-1366.
Bagshawe, K.D., Disese Markers, 9, (1991), 233-238.
Springer, C. J., Anti-Cancer Drug Design, 6, (1991), 467-479.
Springer, C. J., Drugs of the Future, 18(3), (1993), 212-215.
Bagshawe, K.D., Monclonal Antibodies and Immunoconjugates, (1990), 95-102.
Springer, C. J., Monoclonal Antibodies--Antibodies in Clinical Oncology, (1991), 185-191.
Bagshawe, K.D. Proc. 4th Intern. Conf. on Monoclonal Antibody Imunoconjugates for Cancer, (1989), 178.
Sharma, S. K., Disease Markers, 9 (1991), 225-231.
Springer, C. J. Proc. Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, RPMS, UK 34, (1989).
Bagshawe, K.D., Biol. Proc. 17th Intern. Soc. Oncodevelopmental Biology & Medicine, DEX(1989).
Melton, R. G., Proc. NATO Adv. Studies Inst., Greece (1994).
Antoniw, P., Proc., 18th Intern. Soc. Oncodevelopment Biology & Medicine, Russia (1990).
Sharma, S. K. Proc. 18th Intern. Soc. Oncodevelopment Biology & Medicine, Russia (1990).
Springer, C. J., Proc. Adv. in Applications of Monoclonal Antibodies in Clinical Oncology RPMS, UK 23 (1990).
Sunters, C. J. Biochem. Pharmacology, 44(1), (1992), 59-64.
Blakely, D. C., Proc. 9th Intern. Hammersmith Meeting, Porto Carras, Greece 33, (1992).
Springer, C. J., Proc. 9th Intern. Hammersmith Meeting, Advances in Applications of Monoclonal Antibodies in Clinical Oncology, Porto Carras, Greece 35 (1992).
Sunters, A., Br. J. Cancer, 60 (1992).
Blakey, D. C., Br. J. Cancer, 67 (1992).
Sharma, S. K., Proc. Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, London, UK 53 (1989).
Sharma, S. K. Antib. Immunoconj. & Radiopharm. 6 (1993), 74.
Sharma, S. K., Proc. 10th Intern. Hammersmith Meeting--Advances in Applications of Monoclonal Antibodies in Clinical Oncology, Paphos, Cyprus, (1993), 24-25.
Bagshawe, K. D., Antib. Immunoconj. & Radiopharm, (1992), 133.
Springer, C. J., Antib. Immunoconj. & Radiopharm., (1991), 226.
Bagshawe, K. D., Antib. Immunoconj. & Radiopharm, (1991), 204.
Springer, C. J., Antib. Immunoconj. & Radiopharm., (1992), 127.
Bagshawe, K. D., Antib. Immunoconj. & Radiopharm., 4 (1991), 915-922.
Springer, C. J., Proc. 3rd Intern. Conf. on Monoclonal Antibody Immunoconjugates for Cancer, UCSD, USA (1988), 43.
Springer, C. J., Antib. Immunoconj. & Radiopharm. 3 (1990), 61.
Bagshawe, K. D., Proc. 4th Int. Conf. on Monoclonal Antibody Immunoconjugates for Cancer, USCD, USA (1989) 178.
Sharma, S K., Antib. Immunoconj. & Radiopharm., 5, (1992) 348.
Springer, C. J., Antib. Immunoconj. & Radiopharm., 6 (1993), 74.
Springer, C. J., Comparasion of Half Lives and Cytotoxicity of Prodrugs & their Activated Drugs in Antibody Directed Enzyme Prodrug Therapy (Adept); Proc. Targeted Cancer Therapy, London, 1991.
Springer, C. J., Proc 10th Int. Hammersmith Meeting--Advances in Application of Monoclonal Antibodies in Clinical Oncology, Cyprus (1993).
Bagshawe, K.D., (1990) Proc. Advances in Applications of Monoclonal Antibodies in clerical Oncology, London, U.K.
Sharma et al., (1990) Antibody directed enzyme prodrug therapy (ADEPT) in human tumour xenograft models Br. J. Cancer, 62; 487.

Affiliated with

Also associated with

Rating

Process for antibody directed enzyme prodrug therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for antibody directed enzyme prodrug therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for antibody directed enzyme prodrug therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1986393